The first thing that comes to mind when we speak about the S&P 500 is the biggest tech companies, high valuations, and ...

While many of the top income stocks on the market are expensive, some can be had for well under $100 per share. Here are two ...

In this week’s edition of InnovationRx, we look at the battle for Metsera, the departure of FDA’s top drug regulator, ...

Under the terms of the cash deal, Pfizer will pay $65.60 a share upfront and a contingent value right worth up to $20.65 a ...

Pfizer on Tuesday raised its full-year profit forecast for the second quarter in a row as robust demand for its blockbuster ...

We also have a huge number of stocks that are sinking under their own weight, high-quality companies, real companies that are ...

Cogent Biosciences, Inc. stock soars after bezuclastinib's strong Phase 3 results in GIST. Click for my updated look at COGT ...

Pfizer has signed a deal to purchase Metsera Inc., an obesity drugmaker in the development stage, after winning a bidding war against Novo Nordisk. Metsera, based in New York, is developing oral ...

After mulling over competing offers from both Pfizer and Novo Nordisk, Metsera has decided to go with the former’s $10bn ...

How many companies will be left standing once consolidation hits the AI in healthcare sector? Which pharma companies are ...

Biden touts Dems election wins, says Trump is taking 'wrecking ball' to democracy ...

Major U.S. equities indexes rose Monday afternoon amid optimism Congress could soon agree on a spending plan to end the ...